HYPERTENSION RESEARCH, published by SpringerNature, serves as a premier platform in the field of Cardiology and Cardiovascular Medicine, Internal Medicine, and Physiology. Since its inception in 1992, the journal has built a substantial reputation, currently ranked in the second quartile (Q2) across several categories in 2023, reflecting its influence and high-quality contributions to medical research. With a focus on hypertension, the journal aims to disseminate vital research findings, clinical studies, and innovative treatment strategies to a diverse audience of researchers, healthcare professionals, and students, fostering knowledge exchange in the management of hypertensive conditions. Although it is not an Open Access journal, it offers comprehensive access to its extensive archive of valuable resources, ensuring that critical advancements in the understanding of hypertension are both accessible and impactful. HYPERTENSION RESEARCH is not only essential for those directly involved in cardiovascular and internal medicine practices but also for interdisciplinary scholars who are looking to explore the intersections of physiology and other biomedical fields in their work.

DIABETES OBESITY & METABOLISM, published by Wiley, is a premier international journal dedicated to the fields of endocrinology, diabetes, and metabolic disorders. With an impressive impact factor and its status as a Q1 journal in multiple categories—including Endocrinology and Internal Medicine—this publication is highly regarded in the academic community. Since its inception in 1999, the journal has served as a crucial platform for the dissemination of cutting-edge research, reviews, and clinical studies, driving advancements in understanding and treatment of diabetes and obesity. Researchers and professionals alike benefit from its rigorous peer-review process and extensive reach, as it aims to bridge the gap between laboratory findings and clinical applications. Although not an Open Access journal, articles are accessible through institutional subscriptions, ensuring that vital knowledge reaches those committed to enhancing patient care and expanding the scientific body of work in these pivotal areas.

HYPERTENSION, published by Lippincott Williams & Wilkins, is a preeminent journal in the field of cardiovascular medicine, focusing on the latest research, therapies, and clinical practices related to hypertension and its associated disorders. With a distinguished Q1 ranking in Internal Medicine and a commendable Scopus rank of #12 out of 167 in its category, it occupies a vital position within the academic community, appealing to researchers, clinicians, and educators alike. The journal has been disseminating impactful findings since 1979 and continues to influence the discourse on hypertension through rigorous peer-reviewed articles, reviews, and studies designed to elevate understanding and treatment of this prevalent condition. HYPERTENSION remains an essential resource for professionals keen on advancing their knowledge in this critical area of medicine, fostering innovations that ultimately improve patient care.

INTERNATIONAL JOURNAL OF OBESITY, published by SpringerNature, stands as a premier multidisciplinary platform for research in the fields of Endocrinology, Diabetes and Metabolism, Nutrition and Dietetics, as well as Miscellaneous Medicine. With a remarkable impact, the journal is consistently positioned in the Q1 category across these critical areas, underscoring its significance in advancing the understanding of obesity and its related health outcomes. Established in 1977 and covering a broad spectrum of studies until 2024, it boasts a notable Scopus Rank reflecting its influential contributions to the scientific community, including a rank of 14 out of 140 in Nutrition and Dietetics. The INTERNATIONAL JOURNAL OF OBESITY is not just a repository of knowledge but a vital resource for researchers, clinicians, and students aiming to explore the complexities of obesity and develop evidence-based interventions. Despite not being an open-access journal, its rigorous peer-reviewed articles remain accessible to those within academic institutions, facilitating an essential dialogue among professionals dedicated to this critical global health issue.

SCHIZOPHRENIA BULLETIN, published by Oxford University Press, stands as a leading journal in the field of psychiatry and mental health, particularly focusing on the complexities of schizophrenia. Established in 1973, this esteemed journal covers a wide spectrum of research areas, including clinical findings, neurobiology, epidemiology, and treatment approaches, making it indispensable for researchers and practitioners alike. With its current status in the Q1 category of the psychiatry and mental health disciplines, and a remarkable Scopus rank of #34 out of 567, the journal enjoys a strong impact factor, emphasizing its contribution to advancing knowledge in mental health. Although it operates on a subscription model, the significance of the journal in disseminating groundbreaking research makes it a vital resource for those committed to improving outcomes in schizophrenia. Through its rigorous peer-review process and commitment to high-quality scientific communication, SCHIZOPHRENIA BULLETIN continues to be at the forefront of psychiatric research and discourse.

JACC-Heart Failure is a premier journal in the field of cardiology, published by Elsevier Science Ltd, that has rapidly established itself as a vital resource for researchers and practitioners focused on heart failure and cardiovascular health. With an impressive impact factor and ranking in the Q1 category for Cardiology and Cardiovascular Medicine, this journal is recognized for its high-quality peer-reviewed articles that contribute significantly to advancements in clinical practice and scientific understanding of heart failure. As of 2023, the journal ranks #10 out of 387 in its field, positioning it in the 97th percentile of Scopus rankings, which highlights its influential role in disseminating cutting-edge research. Although the journal does not operate under an open-access model, it maintains a rigorous review process, ensuring the publication of articles that are both innovative and clinically relevant. Targeting an audience of dedicated researchers, healthcare professionals, and students, JACC-Heart Failure serves as an essential platform for exploring the complexities of heart failure treatments, management strategies, and future directions in cardiology.

JOURNAL OF HUMAN HYPERTENSION, a prominent publication in the field of internal medicine, is dedicated to advancing the understanding of hypertension and its implications for human health. Published by SPRINGERNATURE in the United Kingdom, this esteemed journal has been a vital resource for researchers and clinicians since its inception in 1987, with a continuous commitment to disseminating high-quality, peer-reviewed research. With an impressive Q2 category rank in Internal Medicine and a Scopus rank of 53 out of 167, it occupies a crucial position within the academic community, reaching a 68th percentile ranking that underscores its significance. The journal aims to provide a platform for innovative studies and reviews, fostering knowledge that bridges basic science, clinical practice, and public health. Although it does not currently offer open access, it remains accessible through institutional subscriptions, ensuring that vital information about hypertension is available to a broad spectrum of healthcare professionals and researchers. Explore the critical findings and groundbreaking research published in the JOURNAL OF HUMAN HYPERTENSION to stay at the forefront of hypertension studies.

Clinical Hypertension is a premier journal dedicated to advancing the field of hypertension and cardiovascular health, published by SpringerNature. Since its transition to an Open Access model in 2014, the journal has opened doors for researchers globally to share their findings without barriers, aiming to foster collaboration and innovation in this vital area of medicine. With a current impact factor that positions it in the Q2 quartile for both Cardiology and Cardiovascular Medicine and Internal Medicine, Clinical Hypertension is recognized for its scholarly contributions, reflected in its Scopus rankings (Rank #100/387 in Cardiology and Rank #52/167 in Internal Medicine), which place it in the top percentiles of these competitive fields. Covering a diverse range of topics within hypertension research, it serves as an essential resource for clinicians, researchers, and students alike, promising to keep its audience informed of the latest developments and breakthroughs from its inception in 2017 through to 2024.

Metabolic Syndrome and Related Disorders is an esteemed journal published by MARY ANN LIEBERT, INC, focusing on the multifaceted aspects of metabolic syndrome, including its interaction with chronic diseases such as diabetes, cardiovascular conditions, and obesity. Since its inception in 2003, this journal has established itself as a vital resource for researchers, healthcare professionals, and students dedicated to advancing knowledge in the fields of endocrinology, internal medicine, and metabolic disorders. With an impact factor reflective of its academic significance, Metabolic Syndrome and Related Disorders is recognized within the Q2 and Q3 quartiles in its respective categories, solidifying its reputation among scientific and clinical communities. Although it does not currently offer open access options, the journal remains committed to disseminating high-quality research and reviews that foster innovative solutions and improve patient outcomes. The journal's gradual convergence towards 2024 presents an exciting opportunity for continued exploration and dialogue about metabolic-related health challenges.

Clinica e Investigacion en Arteriosclerosis is a premier academic journal dedicated to the field of cardiology and cardiovascular medicine, published by ELSEVIER. With its ISSN 0214-9168 and E-ISSN 1578-1879, the journal aims to disseminate high-quality research and innovations in the understanding and treatment of arterial diseases, contributing significantly to both clinical practices and pharmacological advancements. Established in 2007 and continuing into 2024, the journal has garnered recognition with a notable Q3 categorization in both Cardiology and Cardiovascular Medicine and Pharmacology (medical) for 2023, reflecting its impact in the academic community. Researchers and healthcare professionals utilizing this journal will find a diverse range of articles exploring novel therapeutic strategies and epidemiological data, making it an essential resource for advancing knowledge and practice in cardiovascular health. While it does not operate as an open-access journal, the findings published in Clinica e Investigacion en Arteriosclerosis are pivotal for understanding current trends and future directions in cardiovascular research.